SOURCES SOUGHT
A -- Collection of plasma and serum samples from Asian subjects for a metabolomics reference sample set.
- Notice Date
- 6/5/2018
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- SBSS-N02RC82570-61
- Archive Date
- 6/30/2018
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice Number: SBSS-N02RC82570-61 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: June 15, 2018 by 1:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees is being considered. As a result of this Sources Sought Notice, the NCI may issue a combined synopsis solicitation through FedBizOpps. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. Metabolomics is the assessment of small molecules, often defined to be only those molecules participating in cellular metabolism, within a given biological system. Metabolites include low-molecular weight compounds, such as lipids, sugars, amino acids, nucleotides. Modern methods, such as Nuclear Magnetic Resonance (NMR) and Mass Spectroscopy (MS) coupled with liquid chromatography (LC) or gas chromatography (GC), can identify and quantify a large number of metabolites simultaneously within a biospecimen, capturing its metabolomic profile. These profiles have been used to predict the risk of diabetes, diagnose prostate cancer, and identify biomarkers of Crohn's disease. There is a strong interest in applying metabolomic analysis to cancer epidemiologic studies. Unfortunately, unlike in animal studies, sample collection, storage and preparation can be highly variable across studies and even within studies. Such variability in sample processing will likely affect measured metabolite levels and induce artifacts in down-stream analyses. This creates challenges for data harmonization and replication of results. One way to address these challenges is to establish a reference sample set to allow the examination of metabolite-metabolite correlations between platforms, which provides important contextual information, especially if results fail to replicate between studies. Additionally, a reference sample set will support metabolite imputation efforts, such that metabolites missing from one platform may be imputed to the larger data set using prior data collected on inserted reference samples. Finally, quantitative information on metabolite levels in the reference sample set would make it possible to calibrate relative concentrations to absolute concentrations. The aim of this study is to collect a set of reference samples for metabolomics analyses in large-scale epidemiology studies, specifically prospective cohorts. This project will allow for the examination of metabolite-metabolite correlations between platforms to assist with data harmonization across platforms, metabolite imputation, and quantitation of metabolite levels across over 40 cohorts participating in the COnsortium of METabolomics Studies (COMETS). Membership criteria for COMETS is broad allowing any cohort to join if the study is prospective and has at least 100 participants with blood metabolomics data, including identified metabolite data, and follow-up data for disease. Thus, the membership criteria are inclusive and include cohorts from the United States, Europe, Asia, and South America. The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to conduct a collection of plasma and serum samples from Asian subjects for a metabolomics reference sample set. The Contractor shall to provide adequate equipment, supplies, facilities, and scientific materials necessary for carrying out the requirements. The Contractor shall work on several key tasks, including the following: 1. The Contractor shall collect 25 mL each of serum and EDTA plasma, and 11 mL of heparinized plasma from the same 10 individual donors of Asian descent (ages 20-65 years old and residing in the US for less than 3 months). Aliquot the serum and EDTA plasma from each donor as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL, and 5 mL vial of remaining samples. Aliquot the heparinized plasma as follows: 25 X 0.15 mL, 5 X 0.25 mL, 2 x 0.4 mL. 2. The Contractor shall collect 4 mL of serum from each of the same 10 individual donors of Asian descent as collected in 1 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 3. The Contractor shall collect 4 mL of EDTA plasma from each of the same 10 individual donors of Asian descent as collected in 1 and 2 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 4. The Contractor shall collect 1 mL of heparinized plasma from the same 10 individual donors of Asian descent as collected in 1,2 and 3 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 5. The Contractor shall provide remaining serum, EDTA plasma and heparinized plasma separately in one vial. The volume should be a minimum of 5 mL. 6. The Contractor shall label all tubes with a unique identifier that links to subject ID, date drawn, material type (serum or plasma), material modifier (i.e. preservative type), vial type and brand, aliquot volume, volume unit, subject's age, subject's sex, subject's self-reported Asian ethnicity. The sample manifest and identifier scheme must be provided to and approved by the NCI Contracting Officer's Technical Representative (COTR) prior to sample collection. 7. The Contractor shall properly store and ship samples so that no freeze-thaw occurs. Ship samples to the NCI per the instruction of the NCI COTR. Samples should be stored in boxes appropriately slotted for the aliquot sizes, e.g. 100-well boxes for 0.5 ml tubes or 169-well boxes for 0.2 mL tubes. In addition, the Contractor must show that they have the required Institutional Review Board (IRB) and FederalWide Assurance (FWA) approvals to collect the samples. Delivery: Delivery shall be within 90 days after purchase order award. All shipping/handling and delivery fees shall be included. How to Submit a Response: 1. Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2. Due Date: Capability statements are due no later than 1:00PM EST on June 15, 2018. 3. Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov or mailed to the address located under Point of Contact. All questions must be in writing and can be faxed to (240) 276-5399 or emailed. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference number SBSS- N02RC82570-61 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Kathy Elliott 9609 Medical Center Dr., Room 1E226 Bethesda, MD 20892-9705 Elliottk@mail.nih.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/SBSS-N02RC82570-61/listing.html)
- Place of Performance
- Address: 9609 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN04943573-W 20180607/180605230917-2067b733200c4c93868d68518f10f48a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |